Skip to content

PTHS PTHS Xepi Royalty Agreement — Less: current portion

Similar metrics at other companies

Syndax Pharmaceuticals logo
SNDXRoyalty Interest Financing Less Current Portion
$343.91M+3.7%
Aquestive Therapeutics, Inc. logo
AQSTRoyalty obligations, net
$26.91M+24.8%
Scilex Holding Company logo
SCLXScilex Pharma — Royalty Expense
$1.2M+33.3%
Evolus logo
EOLSLong-term portion of contingent royalty obligation payable to Evolus Founders
$17.51M
PVL
PVLARoyalty Agreement Liability
$19.8M+50.5%
Omeros logo
OMERRoyalty Obligation Noncurrent
$141.93M-25.3%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ContractualObligationCurrent.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's xepi royalty agreement — less: current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's xepi royalty agreement — less: current portion?
PTHS (PTHS) reported xepi royalty agreement — less: current portion of $156K in Q1 2026.
What does xepi royalty agreement — less: current portion mean?
Represents the long-term portion of the royalty obligation liability associated with the Xepi license agreement. This figure excludes payments due within the next twelve months, providing insight into the company's long-term financial commitments related to this specific product asset.